Kawasaki’s disease – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Fri, 19 Jun 2026 04:02:53 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Kawasaki’s disease – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Comparing Anakinra versus Immunoglobulin for Treatment-Resistant Kawasaki Disease in Patients Who Failed Initial Immunoglobulin Therapy https://clinicaltrials.eu/trial/study-comparing-anakinra-and-human-normal-immunoglobulin-for-kawasaki-disease-in-patients-not-responding-to-initial-treatment/ Wed, 29 Apr 2026 14:58:09 +0000 https://clinicaltrials.eu/trial/study-comparing-anakinra-and-human-normal-immunoglobulin-for-kawasaki-disease-in-patients-not-responding-to-initial-treatment/ This study focuses on Kawasaki disease, a condition that causes inflammation in blood vessels throughout the body. The research compares two different treatments for patients who did not respond well to their initial therapy. The treatments being studied are Anakinra, which is given as an injection under the skin, and intravenous immunoglobulin (IVIG), which is given through a vein.

The purpose of this research is to determine which of these two treatments works better in reducing fever in patients with Kawasaki disease who did not improve after their first standard treatment. The study will use Kineret (the brand name for Anakinra) as an injection and Privigen (a type of immunoglobulin) as an infusion.

During the study, patients will receive either Anakinra injections or a second round of immunoglobulin treatment. The doctors will monitor the patients’ temperature and overall health status. They will also check the patients’ heart health using special tests, as Kawasaki disease can affect the heart’s blood vessels. The study will continue to monitor patients for several weeks to ensure their safety and to see how well the treatments work.

]]>